ENGAGE: A phase 3 Multicentre, randomised, double blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic Alzheimer’s Disease
DEMENTIA TRIALS AUSTRALIA
ENGAGE: A phase 3 Multicentre, randomised, double blind, placebo controlled, parallel-group study to evaluate the efficacy and safety of BIIB037 in subjects with early symptomatic Alzheimer’s Disease